The Safe and Economical Care of Ta Bladder Cancer

Hugh Mostafid, Roger Kirby, John M. Fitzpatrick, Richard T. Bryan

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
252 Downloads (Pure)



Stage Ta bladder cancer accounts for around half of all new cases of urothelial bladder cancer. It shows heterogeneous behavior with a 5-year recurrence rate of 31% to 78% and a progression rate of 0.8% to 45%. Optimal management is crucial to achieve safe and yet economical long-term outcomes. We provide an overview of such management.


Using AUA, NCCN®, EAU and ICUD-EAU guidelines as the basis of this nonsystematic review we performed PubMed® searches to update the literature in this field and expand on topics of particular interest or controversy.


This study provides an overview for the practicing urologist of safe, economical care of stage Ta bladder cancer with regard to risk stratification, preoperative and perioperative care, subsequent adjuvant treatment, surveillance, recurrence management and long-term outcomes. While these recommendations are already incorporated in current guidelines, some aspects deserve further discussion or have been the subject of relevant research subsequent to guideline publication.


The traditional view that stage Ta bladder cancer is invariably synonymous with low risk disease requires reevaluation. Modern management of stage Ta bladder cancer depends on initial risk stratification that allows for subsequent management based on a number of evidence-based guidelines. Given the usual long clinical course of stage Ta bladder cancer, such an approach ensures not only safe but also economical care of this group of patients.
Original languageEnglish
Pages (from-to)176-183
Number of pages8
JournalUrology Practice
Issue number4
Early online date23 Aug 2014
Publication statusPublished - Nov 2014


  • urinary bladder
  • carcinoma
  • papillary
  • evidence-based practice
  • practice guideline
  • risk


Dive into the research topics of 'The Safe and Economical Care of Ta Bladder Cancer'. Together they form a unique fingerprint.

Cite this